Supplementary Material for: Objective response and progression free survival contribute to prolong overall survival in atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma.

Kazuto Tajiri (寄稿者)
Kenichiro Tsukada (寄稿者)
Yoshiharu Tokimitsu (寄稿者)
Yuchi Motofuji (寄稿者)
Kengo Kawai (寄稿者)
Nozomu Muraishi (寄稿者)
Aiko Murayama (寄稿者)
Yuka Hayashi (寄稿者)
Y. Shimizu (寄稿者)
Ichiro Yasuda (寄稿者)

内科学（第三）講座

データセット

1 学術論文

1 件

フィルター

2024
Objective Response and Progression-Free Survival Contribute to Prolong Overall Survival in Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma
Tajiri, K., Tsukada, K., Tokimitsu, Y., Motofuji, Y., Kawai, K., Muraishi, N., Murayama, A., Hayashi, Y., Shimizu, Y. & Yasuda, I., 2024/02/01, In: Oncology (Switzerland). 102, 2, p. 131-140 10 p.
研究成果: ジャーナルへの寄稿 › 学術論文 › 査読
2 被引用数 (Scopus)